Results 71 to 80 of about 49,464 (141)

Radiological Response to Capecitabine and Temozolomide in an Elderly Patient with Metastatic Leiomyosarcoma: A Case Report. [PDF]

J Clin Med
Yalcin S, Kilinc C, Sahin TK, Dizdar O.
europepmc   +1 more source

Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial. [PDF]

Nat Commun
Wang J, Ouyang Q, Xie W, Niu Z, Zhang Q, Yan X, Teng Y, Chang J, Cheng Y, Wang A, Wang J, Yao H, Yang Z, Sun T, Tong Z, Wu X, Wang Y, Zhou E, Kong X, Wang X, Zeng, Gu S, Hou Y, Gao D, Qu Z, Han C, Fang J, Xu B.   +27 more
europepmc   +1 more source

Capecitabine-Induced Hand-Foot Syndrome With Genital Involvement. [PDF]

J Adv Pract Oncol
Feng Y, Baroody C, Al Mutar S.
europepmc   +1 more source

Efficacy and Safety Ranking of HER2-Targeted TKIs in Advanced Breast Cancer: A Bayesian Network Meta-Analysis. [PDF]

Clin Med Insights Oncol
Li R, Huangfu R, Lan H, Zhang C, Hou K, Ping Y.   +5 more
europepmc   +1 more source

Clinical Decision-Making After Receptor Conversion Following Neoadjuvant Therapy in Breast Cancer: A Three-Strategy Framework. [PDF]

J Clin Med
Pogoda K, Czopowicz M, Olszewski W, Durzynska M, Wysocki PJ.   +4 more
europepmc   +1 more source

Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysis. [PDF]

ESMO Open
Shitara K, Rha SY, Klempner SJ, Lordick F, Ranganath R, Oh M, Getzenberg RH, Gourgioti G, Chai X, Yang H.   +9 more
europepmc   +1 more source

Low-intensity induction chemotherapy before chemoradiotherapy for rectal cancer: 10-year overall survival in the LARC-RRP trial. [PDF]

Br J Radiol
Ree AH, Meltzer S, Flatmark K, Dueland S.   +3 more
europepmc   +1 more source

Toxicity outcomes of concurrent radiotherapy with adjuvant capecitabine in triple-negative breast cancer (TROD 06-24). [PDF]

Discov Oncol
Demircan V, Benli Yavuz B, Bakkal BH, Celikarslan S, Karabulut Gul S, Tepetam H, Colpan Oksuz D, Arslan A, Altinok A.   +8 more
europepmc   +1 more source

Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France. [PDF]

Breast
Frenel J, de Nonnevile A, Guerin-Charbonnel C, Zeghondy J, Mathiot L, Mailliez A, Poumeaud F, Isambert N, Arnedos M, Le Du F, Galland L, Kabirian R, Guiu S, Poestch L, Deluche E, Cherifi F, Dalenc F, Volant E, Pistilli B, San T, Bachelot T, Patsouris A, Bocquet F, Bailleux C, Loirat D, Larrouquere L.   +25 more
europepmc   +1 more source

Predictive Biomarkers of Metronomic Chemotherapy Response in Solid Tumors: Chasing an Elusive Signal. [PDF]

Cancers (Basel)
Wysocki PJ, Kwinta Ł, Wysocka E.
europepmc   +1 more source